Recruiting

Rehabilitation Program for People With Methamphetamine-Associated Cardiopulmonary Conditions

The purpose of this study is to evaluate the feasibility and preliminary effectiveness of increasing control over stimulant use and physical health through incentivized rehabilitation (INSPIRE). INSPIRE is a 12-week remotely-delivered collaborative care intervention for rural patients with Methamphetamine-Associated Heart Failure (Me-HF) or Methamphetamine-Associated Pulmonary Arterial Hypertension (Me-PAH) featuring smartphone-based contingency management incentivizing participation in remote synchronous…

I'm interested View official listing
ClinicalTrials.gov IDNCT07915882
PhaseNA
Enrollment45
SponsorMichael Incze
Age18 Years and older
SexALL
I'm interested View official listing

Conditions studied

Methamphetamine-Associated Heart Failure, Methamphetamine-Associated Pulmonary Arterial Hypertension

About this study

The purpose of this study is to evaluate the feasibility and preliminary effectiveness of increasing control over stimulant use and physical health through incentivized rehabilitation (INSPIRE). INSPIRE is a 12-week remotely-delivered collaborative care intervention for rural patients with Methamphetamine-Associated Heart Failure (Me-HF) or Methamphetamine-Associated Pulmonary Arterial Hypertension (Me-PAH) featuring smartphone-based contingency management incentivizing participation in remote synchronous rehabilitation.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Active methamphetamine use determined by positive urine drug testing within the past 3 months and/or self-reported current use * Current diagnosis of chronic heart failure or pulmonary hypertension documented in the electronic health record * Possession of a smartphone * Able to participate in virtual exercise rehabilitation Exclusion Criteria: * Currently incarcerated * Unable to interact with smartphone app and/or virtual health coaching sessions in English * Unstable arrhythmia, defined as any known arrhythmia that is associated with hemodynamic effects like syncope, hypotension, or decompensated heart failure * Decompensated chronic heart failure or pulmonary hypertension * NYHA class IV symptoms * Myocardial infarction within the past 3 months, percutaneous coronary intervention within the past 2 weeks, coronary artery bypass graft within the past 3 months, or implantable cardiac defibrillator/cardiac resynchronization therapy/pacemaker implantation within the last 6 weeks * Unstable angina, uncontrolled hypertension, acute myocarditis/pericarditis, intracardiac thrombus * Severe symptomatic aortic stenosis

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-18.